Compare WNC & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNC | PEPG |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.1M | 317.6M |
| IPO Year | 1991 | 2022 |
| Metric | WNC | PEPG |
|---|---|---|
| Price | $9.07 | $5.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $9.00 | ★ $9.50 |
| AVG Volume (30 Days) | 509.2K | ★ 831.0K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 6.15 | N/A |
| Revenue | ★ $1,638,115,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.72 | N/A |
| P/E Ratio | $1.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.78 | $0.88 |
| 52 Week High | $20.63 | $6.85 |
| Indicator | WNC | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 63.99 | 51.14 |
| Support Level | $8.40 | $5.04 |
| Resistance Level | $9.02 | $6.72 |
| Average True Range (ATR) | 0.33 | 0.58 |
| MACD | 0.19 | -0.04 |
| Stochastic Oscillator | 89.77 | 28.54 |
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.